Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Accelerated Approval Integrity Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.6963 - Accelerated Approval Integrity Act of 2022; All Provisions
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · second_quarter · Q2
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Food and Drug Amendments of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
American Data Privacy and Protection Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Matters related to Gene Therapy funding
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.2158 - Newborn Screening Saves Lives Reauthorization Act of 2019
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Prescription Drug Pricing Reduction Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
2022 · first_quarter · Q1
H.R.6963 - Accelerated Approval Integrity Act of 2022; All Provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · fourth_quarter · Q4
H.R.4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Matters related to Gene Therapy funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · third_quarter · Q3
Introduction to company, matters affecting regulatory policy and innovation
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · second_quarter · Q2
Medicaid Coverage and Access, Center for Biologics Evaluation and Research Funding, Gene Therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · fourth_quarter · Q4
Matters regarding FDA topics and gene therapy
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · second_quarter · Q2
CURES 2.0; Health Care Coverage Modernization; Regulatory Modernization
Filing targets: HOUSE OF REPRESENTATIVES
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · first_quarter · Q1
S.2158 - Newborn Screening Saves Lives Reauthorization Act of 2019
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · fourth_quarter · Q4
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · third_quarter · 3A
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · third_quarter · Q3
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · second_quarter · 2A
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · first_quarter · 1A
Newborn Screening Saves Lives Reauthorization Act; Value and Efficiency Act; Patient Affordability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · second_quarter · Q2
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · first_quarter · Q1
Newborn Screening Saves Lives Reauthorization Act; Value and Efficiency Act; Patient Affordability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2018 · fourth_quarter · Q4
Communication regarding education and outreach of company; Communication regarding Newborn Screening Saves Lives Reauthorization Act; Communication regarding Medicaid access and approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2018 · third_quarter · Q3
Communication regarding education and outreach of company; Communication regarding Newborn Screening Saves Lives Reauthorization Act; Communication regarding guidance on Indications and Usage Section of Labeling
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2018 · second_quarter · Q2
Request support for enforcement of existing law